Holliday parts ways with Digitas Health

Share this article:

Linda Holliday, co-founder and longtime president of the company now known as Digitas Health, has left the agency.

Holliday described her parting of ways with the interactive firm she helped create nearly 20 years ago as amicable. “I'm still in touch with some clients and still doing some odds and ends,” she told MM&M.

Holliday said she may be working on a few consulting projects throughout the summer but, as of yet, has not solidified a permanent new role. “I may go on to do something new again because that's what I enjoy,” Holiday said.

Holliday's former duties have been divided between members of the Digitas Health executive team, overseen by CEO and co-founder David Kramer.

That executive team consists of:
*Michael du Toit, EVP, marketing & client services,
*Larry Mickelberg, EVP, strategy & new business,
*Len Dolce, general manager,
*Dr. Michael Golub, chief medical officer,
*Alexandra (Alex) vonPlato, chief creative officer.

In April, the Philadelphia-based interactive healthcare agency changed its name from Medical Broadcasting Company to Digitas Health to reflect its January 2006 acquisition by Publicis-owned Digitas.

The agency's client roster includes Wyeth, AstraZeneca, Celgene, Bristol-Myers Squibb, Roche, Merck, GlaxoSmithKline and others.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Eli Lilly and BI's Jardiance hits shelves

Eli Lilly and BI's Jardiance hits shelves

The new SGLT-2 inhibitor is on shelves less than a month after FDA approval.

PhRMA Urges Court to Reject Off-Label Promotion Case

PhRMA Urges Court to Reject Off-Label Promotion Case

The Pharmaceutical Research and Manufacturers of America (PhRMA) says a California federal court should dismiss a whistleblower's False Claims Act suit against three drug companies on First Amendment grounds

Five things for Pharma Marketers to know: Tuesday, August 26

Five things for Pharma Marketers to know: Tuesday, ...

Merck and Pfizer pursue new pembrolizumab research, black box warnings are linked to fewer court visits, and the WHO says it needs $430M to fight Ebola.